Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ATAI Life Sciences
Biotech
Atai's schizophrenia drug fails to improve cognition in phase 2
Atai Life Sciences’ schizophrenia drug has failed to improve cognition in a phase 2 study.
James Waldron
Jul 28, 2025 7:45am
Beckley Psytech psychedelic reduces depression symptoms in ph. 2
Jul 1, 2025 8:30am
Atai, Eli Lilly, Novartis & more—Chutes & Ladders
May 17, 2024 8:30am
2 months after depression fail, Atai lays off 30% of staff
Mar 6, 2023 11:20am
Atai drops pipeline assets, takes on debt to extend cash runway
Aug 15, 2022 7:00am
Psychedelics inch toward approval, but market may not be ready
Aug 17, 2021 10:40am
